吉维司他治疗杜氏肌营养不良男孩的安全性和有效性(EPIDYS):一项多中心、随机、双盲、安慰剂对照的3期试验
EPIDYS是一项在11个国家41个中心进行的3期随机双盲安慰剂对照试验,纳入179例至少6岁、接受全身糖皮质激素治疗的可行走杜氏肌营养不良男孩,按2:1随机接受口服吉维司他或安慰剂治疗72周。主要终点为A组(大腿外侧肌脂肪分数>5%且≤30%)基线至72周四级爬梯评估变化,吉维司他组几何最小二乘均值比1.27(95%CI 1.17-1.37),安慰剂组1.48(95%CI 1.32-1.66),比值0.86(95%CI 0.745-0.989;p=0.035)。两组四級爬梯评估均恶化,但吉维司他组下降显著较小;最常见不良事件为腹泻和呕吐,无治疗相关死亡。
要点
- 在A组可行走杜氏肌营养不良男孩中,吉维司他组72周四级爬梯评估的恶化程度显著小于安慰剂组(比值0.86,95%CI 0.745-0.989;p=0.035)。
- 吉维司他组腹泻发生率为36%(43/118),安慰剂组为18%(11/61);呕吐分别为29%(34/118)和13%(8/61)。
- 研究期间两组四級爬梯评估均恶化,但吉维司他组下降显著较小;未发生治疗相关死亡。
核心结论
- 在可行走的杜氏肌营养不良男孩中,研究期间两组四級爬梯评估结果均恶化,但吉维司他组的下降显著小于安慰剂组。
- 吉维司他在 interim 安全性分析后降低了剂量,但未报告新的安全性信号。
- 一项正在进行的扩展研究正在评估吉维司他在杜氏肌营养不良患者中的长期安全性和有效性。
研究设计与样本
- 多中心、随机、双盲、安慰剂对照的3期试验,在11个国家的41个三级医疗中心进行。
- 纳入标准:可行走、男性、年龄至少6岁、基因确诊杜氏肌营养不良、两次四級爬梯评估均值≤8秒(差值≤1秒)、从仰卧起立时间至少3秒但小于10秒、已接受全身糖皮质激素至少6个月。
- 179例男孩按2:1随机分配至口服吉维司他(118例)或匹配安慰剂(61例),每日两次,治疗72周,按合并类固醇使用分层。
- 根据基线大腿外侧肌脂肪分数(VLFF,磁共振波谱测定)分组:A组VLFF>5%且≤30%,B组VLFF≤5%或>30%。
- 主要终点在意向治疗A组人群中比较吉维司他与安慰剂对基线至72周四級爬梯评估变化的影响;安全性在所有至少接受一剂研究药物的随机男孩中评估。
主要发现
- 2017年6月6日至2022年2月22日,评估359例男孩资格,179例入组(中位年龄9.8岁,IQR 8.1-11.0),170例(95%)完成研究。
- 179例入组男孩中,120例(67%)在A组(吉维司他81例,安慰剂39例),其中114例(95%)完成研究。
- A组中,基线至72周四級爬梯评估的几何最小二乘均值比:吉维司他组1.27(95%CI 1.17-1.37),安慰剂组1.48(95%CI 1.32-1.66),比值0.86(95%CI 0.745-0.989;p=0.035)。
- 吉维司他组最常见不良事件为腹泻(43/118,36% vs 安慰剂组11/61,18%)和呕吐(34/118,29% vs 8/61,13%);无治疗相关死亡。
关键数值与推荐
- 主要终点分析显示,吉维司他组四級爬梯评估的几何最小二乘均值比为1.27(95%CI 1.17-1.37),安慰剂组为1.48(95%CI 1.32-1.66),比值0.86(95%CI 0.745-0.989;p=0.035)。
- 腹泻发生率:吉维司他组36%(43/118)vs 安慰剂组18%(11/61);呕吐发生率:吉维司他组29%(34/118)vs 安慰剂组13%(8/61)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Duchenne muscular dystrophy, the most common childhood muscular dystrophy, is caused by dystrophin deficiency. Preclinical and phase 2 study data have suggested that givinostat, a histone deacetylase inhibitor, might help to counteract the effects of this deficiency. We aimed to evaluate the safety and efficacy of givinostat in the treatment of Duchenne muscular dystrophy. METHODS: This multicentre, randomised, double-blind, placebo-controlled, phase 3 trial was done at 41 tertiary care sites in 11 countries. Eligible participants were ambulant, male, and aged at least 6 years, had a genetically confirmed diagnosis of Duchenne muscular dystrophy, completed two four-stair climb assessments with a mean of 8 s or less (≤1 s variance), had a time-to-rise of at least 3 s but less than 10 s, and had received systemic corticosteroids for at least 6 months. Participating boys were randomly assigned (2:1, allocated according to a list generated by the interactive response technology provider) to receive either oral givinostat or matching placebo twice a day for 72 weeks, stratified by concomitant steroid use. Boys, investigators, and site and sponsor staff were masked to treatment assignment. The dose was flexible, based on weight, and was reduced if not tolerated. Boys were divided into two groups on the basis of their baseline vastus lateralis fat fraction (VLFF; measured by magnetic resonance spectroscopy): group A comprised boys with a VLFF of more than 5% but no more than 30%, whereas group B comprised boys with a VLFF of 5% or less, or more than 30%. The primary endpoint compared the effects of givinostat and placebo on the change in results of the four-stair climb assessment between baseline and 72 weeks, in the intention-to-treat, group A population. Safety was assessed in all randomly assigned boys who received at least one dose of study drug. When the first 50 boys in group A completed 12 months of treatment, an interim futility assessment was conducted, after which the sample size was adapted using masked data from the four-stair climb assessments. Furthermore, the starting dose of givinostat was reduced following a protocol amendment. This trial is registered with ClinicalTrials.gov, NCT02851797, and is complete. FINDINGS: Between June 6, 2017, and Feb 22, 2022, 359 boys were assessed for eligibility. Of these, 179 were enrolled into the study (median age 9·8 years [IQR 8·1-11·0]), all of whom were randomly assigned (118 to receive givinostat and 61 to receive placebo); 170 (95%) boys completed the study. Of the 179 boys enrolled, 120 (67%) were in group A (81 givinostat and 39 placebo); of these, 114 (95%) completed the study. For participants in group A, comparing the results of the four-stair climb assessment at 72 weeks and baseline, the geometric least squares mean ratio was 1·27 (95% CI 1·17-1·37) for boys receiving givinostat and 1·48 (1·32-1·66) for those receiving placebo (ratio 0·86, 95% CI 0·745-0·989; p=0·035). The most common adverse events in the givinostat group were diarrhoea (43 [36%] of 118 boys vs 11 [18%] of 61 receiving placebo) and vomiting (34 [29%] vs 8 [13%]); no treatment-related deaths occurred. INTERPRETATION: Among ambulant boys with Duchenne muscular dystrophy, results of the four-stair climb assessment worsened in both groups over the study period; however, the decline was significantly smaller with givinostat than with placebo. The dose of givinostat was reduced after an interim safety analysis, but no new safety signals were reported. An ongoing extension study is evaluating the long-term safety and efficacy of givinostat in patients with Duchenne muscular dystrophy. FUNDING: Italfarmaco.
引用
- Mercuri E, Vilchez JJ, Boespflug-Tanguy O, et al. Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2024. PMID: 38508835. doi:10.1016/S1474-4422(24)00036-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。